GlassScriptPhysician profile
Heidi Egloff
NPI 1487093274
$3,488.44
in general payments reported to CMS, 2019-2025
23 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $27.10 · 2021: $77.04 · 2022: $112 · 2023: $677 · 2024: $1,593 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,030 · Food and Beverage: $929 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,029.70 |
| Food and Beverage | $928.91 |
| Education | $169.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,303.96 | 2019-2025 | |
| Genentech USA, INC. | $180.90 | 2019-2024 | Tecentriq, Alecensa, Rozlytrek |
| Gilead Sciences, INC. | $143.80 | 2021-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $105.35 | 2022-2023 | Keytruda, Lynparza |
| Amgen INC. | $104.99 | 2021-2023 | Xgeva, Nplate, Prolia |
| Astellas Pharma US INC | $82.38 | 2023-2024 | Xospata |
| Celgene Corporation | $79.75 | 2023-2024 | Pomalyst, Reblozyl, Opdualag |
| Seagen INC. | $69.99 | 2023 | |
| Foundation Medicine, INC. | $65.03 | 2019 | |
| Eisai INC. | $53.28 | 2019-2024 | |
| Daiichi Sankyo INC. | $52.05 | 2022-2024 | Vanflyta |
| Lilly USA, LLC | $31.64 | 2023-2024 | Verzenio, Jaypirca |
| Pfizer INC. | $26.71 | 2020-2023 | |
| Stemline Therapeutics INC. | $26.34 | 2024 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $24.66 | 2025 | Opdivo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.44 | 2023 | Ojjaara |
| Agios Pharmaceuticals, INC. | $20.93 | 2019 | |
| Abbvie INC. | $16.90 | 2024 | |
| Jazz Pharmaceuticals INC. | $16.63 | 2024 | |
| Servier Pharmaceuticals LLC | $16.11 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2021 | |
| Sirtex Medical INC | $14.66 | 2022-2023 | Sir-Spheres Microspheres |
| Alnylam Pharmaceuticals INC. | $13.98 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Egloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.